Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma
Public ClinicalTrials.gov record NCT00003616. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I/II Trial of Irinotecan (CPT-11) in Patients With Recurrent Malignant Glioma
Study identification
- NCT ID
- NCT00003616
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Enrollment
- Not listed
Conditions and interventions
Conditions
Interventions
- irinotecan hydrochloride Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 120 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 21, 1998
- Primary completion
- May 16, 2002
- Completion
- Dec 19, 2005
- Last update posted
- Jun 26, 2018
1998 – 2005
United States locations
- U.S. sites
- 10
- U.S. states
- 6
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Jonsson Comprehensive Cancer Center, UCLA | Los Angeles | California | 90095-1781 | — |
| UCSF Cancer Center and Cancer Research Institute | San Francisco | California | 94143-0128 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| University of Michigan Comprehensive Cancer Center | Ann Arbor | Michigan | 48109-0752 | — |
| University of Pittsburgh Cancer Institute | Pittsburgh | Pennsylvania | 15213-3489 | — |
| Children's Hospital of Pittsburgh | Pittsburgh | Pennsylvania | 15213 | — |
| Simmons Cancer Center - Dallas | Dallas | Texas | 75235-9154 | — |
| University of Texas - MD Anderson Cancer Center | Houston | Texas | 77030-4009 | — |
| University of Texas Health Science Center at San Antonio | San Antonio | Texas | 78284-7811 | — |
| University of Wisconsin Comprehensive Cancer Center | Madison | Wisconsin | 53792-6164 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00003616, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 26, 2018 · Synced May 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00003616 live on ClinicalTrials.gov.